RU2007129844A - Дополненные матриксы для лечения переломов костей - Google Patents
Дополненные матриксы для лечения переломов костей Download PDFInfo
- Publication number
- RU2007129844A RU2007129844A RU2007129844/15A RU2007129844A RU2007129844A RU 2007129844 A RU2007129844 A RU 2007129844A RU 2007129844/15 A RU2007129844/15 A RU 2007129844/15A RU 2007129844 A RU2007129844 A RU 2007129844A RU 2007129844 A RU2007129844 A RU 2007129844A
- Authority
- RU
- Russia
- Prior art keywords
- pth
- domain
- matrix
- composition according
- fusion peptide
- Prior art date
Links
- 208000010392 Bone Fractures Diseases 0.000 title claims 5
- 239000011159 matrix material Substances 0.000 claims 16
- 239000000203 mixture Substances 0.000 claims 15
- 230000003190 augmentative effect Effects 0.000 claims 10
- 108090000765 processed proteins & peptides Proteins 0.000 claims 10
- 230000004927 fusion Effects 0.000 claims 9
- 239000002243 precursor Substances 0.000 claims 8
- 102000009123 Fibrin Human genes 0.000 claims 7
- 108010073385 Fibrin Proteins 0.000 claims 7
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims 7
- 229950003499 fibrin Drugs 0.000 claims 7
- 230000015556 catabolic process Effects 0.000 claims 6
- 238000006731 degradation reaction Methods 0.000 claims 6
- 239000000758 substrate Substances 0.000 claims 5
- 239000008187 granular material Substances 0.000 claims 4
- OGBMKVWORPGQRR-UMXFMPSGSA-N teriparatide Chemical compound C([C@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)[C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CNC=N1 OGBMKVWORPGQRR-UMXFMPSGSA-N 0.000 claims 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 3
- 108010049003 Fibrinogen Proteins 0.000 claims 3
- 102000008946 Fibrinogen Human genes 0.000 claims 3
- 108090000190 Thrombin Proteins 0.000 claims 3
- 239000011575 calcium Substances 0.000 claims 3
- 229910052791 calcium Inorganic materials 0.000 claims 3
- 229940012952 fibrinogen Drugs 0.000 claims 3
- 229960004072 thrombin Drugs 0.000 claims 3
- 108010000196 Factor XIIIa Proteins 0.000 claims 2
- 108060008539 Transglutaminase Proteins 0.000 claims 2
- 239000001506 calcium phosphate Substances 0.000 claims 2
- 238000004132 cross linking Methods 0.000 claims 2
- 229910052588 hydroxylapatite Inorganic materials 0.000 claims 2
- 229910052500 inorganic mineral Inorganic materials 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000011707 mineral Substances 0.000 claims 2
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 238000011200 topical administration Methods 0.000 claims 2
- 102000003601 transglutaminase Human genes 0.000 claims 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims 2
- 229940078499 tricalcium phosphate Drugs 0.000 claims 2
- 229910000391 tricalcium phosphate Inorganic materials 0.000 claims 2
- 235000019731 tricalcium phosphate Nutrition 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 1
- 230000007515 enzymatic degradation Effects 0.000 claims 1
- 230000002255 enzymatic effect Effects 0.000 claims 1
- 230000003301 hydrolyzing effect Effects 0.000 claims 1
- 229940126601 medicinal product Drugs 0.000 claims 1
- 230000004962 physiological condition Effects 0.000 claims 1
- 210000002303 tibia Anatomy 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/02—Inorganic materials
- A61L27/12—Phosphorus-containing materials, e.g. apatite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
- A61L27/225—Fibrin; Fibrinogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
- A61L27/227—Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/40—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
- A61L27/44—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
- A61L27/46—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix with phosphorus-containing inorganic fillers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/635—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/02—Materials or treatment for tissue regeneration for reconstruction of bones; weight-bearing implants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Endocrinology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Materials Engineering (AREA)
- Composite Materials (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Materials For Medical Uses (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (23)
1. Композиция, включающая в себя
а) пептид, выбранный из группы, состоящей из ПТГ и пептида слияния ПТГ;
б) гранулярный материал, представляющий собой кальцийсодержащее минеральное вещество; и
в) композицию, способную образовывать фибриновый матрикс в физиологических условиях, содержащую компонент-предшественник фибриногена и компонент-предшественник тромбина,
где ПТГ или пептид слияния ПТГ присутствуют в диапазоне концентраций от 0,01 до 2 мг/мл фибринового матрикса или компонентов-предшественников, образующих матрикс, при условии, что концентрация 0,4 мг/мл фибринового матрикса или компонентов-предшественников, образующих матрикс, не включена в указанный интервал значений.
2. Композиция по п.1, в которой компонент-предшественник фибриногена или компонент-предшественник тромбина дополнительно содержит источник кальция.
3. Композиция по п.1, в которой пептид слияния ПТГ содержит по меньшей мере два домена, где первый домен содержит ПТГ, а второй домен содержит субстратный домен, способный к образованию поперечных сшивок.
4. Композиция по п.3, где ПТГ выбран из группы, состоящей из ПТГ1-84, ПТГ1-38, ПТГ1-34, ПТГ1-31 и ПТГ1-25.
5. Композиция по п.4, где ПТГ представляет собой ПТГ1-34.
6. Композиция по п.3, где второй домен представляет собой домен субстрата трансглутаминазы.
7. Композиция по п.6, где трансглутаминазный домен содержит домен субстрата фактора XIIIa.
8. Композиция по п.3, где пептид слияния ПТГ дополнительно содержит сайт деградации между первым и вторым доменами.
9. Композиция по любому из пп.1-8, где гранулярный материал представляет собой смесь трикальцийфосфата и гидроксиапатита.
10. Набор, содержащий композицию по любому из пп.1-9.
11. Набор по п.10, в котором компонент-предшественник фибриногена и компонент-предшественник тромбина отделены друг от друга.
12. Набор по п.10 или 11, где пептид слияния ПТГ дополнительно содержит сайт деградации между первым и вторым доменами, причем указанный сайт деградации может быть сайтом либо ферментативной, либо гидролитической деградации.
13. Дополненный матрикс, включающий в себя
а) ПТГ или пептид слияния ПТГ;
б) гранулярный материал, представляющий собой кальцийсодержащее минеральное вещество; и
в) фибрин,
где указанный ПТГ или пептид слияния ПТГ присутствуют в диапазоне концентраций от 0,01 до 2 мг/мл фибринового матрикса, при условии, что концентрация 0,4 мг/мл фибринового матрикса не включена в указанный интервал значений.
14. Дополненный матрикс по п.13, где ПТГ выбран из группы, состоящей из ПТГ1-84, ПТГ1-38, ПТГ1-34, ПТГ1-31 и ПТГ1-25.
15. Дополненный матрикс по п.14, где ПТГ представляет собой ПТГ1-34.
16. Дополненный метрике по п.13, где дополненный метрике образуется из композиции, способной к формированию фибринового матрикса, и пептида слияния, содержащего ПТГ в качестве первого домена и субстратный домен, способный к образованию ковалентных поперечных сшивок, в качестве второго домена.
17. Дополненный матрикс по п.16, где второй домен представляет собой домен субстрата фактора XIIIa.
18. Дополненный матрикс по любому из пп.13-17, где пептид слияния ПТГ дополнительно содержит сайт деградации между первым и вторым доменами.
19. Дополненный матрикс по п.18, где сайт деградации является сайтом ферментативной деградации.
20. Дополненный матрикс по п.13, где гранулярный материал представляет собой смесь трикальцийфосфата и гидроксиапатита.
21. Применение дополненного матрикса по любому из пп.13-20 для производства лекарственного средства, предназначенного для местного введения с целью лечения переломов костей.
22. Применение композиции по любому из пп.1-9 для производства лекарственного средства, предназначенного для местного введения с целью лечения переломов костей.
23. Применение по п.21 или 22, где перелом кости представляет собой перелом лучевой кости или большеберцовой кости.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US64171505P | 2005-01-06 | 2005-01-06 | |
| US60/641,715 | 2005-01-06 | ||
| US64264405P | 2005-01-10 | 2005-01-10 | |
| US60/642,644 | 2005-01-10 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2007129844A true RU2007129844A (ru) | 2009-02-20 |
| RU2422172C2 RU2422172C2 (ru) | 2011-06-27 |
Family
ID=36581768
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2007129844/15A RU2422172C2 (ru) | 2005-01-06 | 2006-01-06 | Дополненные матриксы для лечения переломов костей |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20060148704A1 (ru) |
| EP (3) | EP3111966B1 (ru) |
| JP (2) | JP5328153B2 (ru) |
| KR (1) | KR20070108170A (ru) |
| AU (1) | AU2006204461C1 (ru) |
| BR (1) | BRPI0606409A2 (ru) |
| CA (1) | CA2592973A1 (ru) |
| ES (2) | ES2902872T3 (ru) |
| MX (1) | MX2007008319A (ru) |
| RU (1) | RU2422172C2 (ru) |
| SG (1) | SG161218A1 (ru) |
| WO (1) | WO2006072622A2 (ru) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8852240B2 (en) | 2004-10-25 | 2014-10-07 | Kieran Murphy, Llc | Methods and compositions for fostering and preserving bone growth |
| US8575101B2 (en) | 2005-01-06 | 2013-11-05 | Kuros Biosurgery Ag | Supplemented matrices for the repair of bone fractures |
| ES2359526T3 (es) | 2006-05-26 | 2011-05-24 | Baxter International Inc. | Agente inyectable para el relleno de huecos óseos. |
| DE602007012693D1 (de) | 2006-05-26 | 2011-04-07 | Baxter Healthcare Sa | Injizierbare fibrin-zusammensetzung zur knochenverstärkung |
| US9066994B2 (en) * | 2006-08-31 | 2015-06-30 | Warsaw Orthopedic, Inc. | Demineralized cancellous strip DBM graft |
| US8388626B2 (en) * | 2006-11-08 | 2013-03-05 | Warsaw Orthopedic, Inc. | Methods of employing calcium phosphate cement compositions and osteoinductive proteins to effect vertebrae interbody fusion absent an interbody device |
| SI3345607T1 (sl) * | 2006-12-29 | 2023-03-31 | Ossifi-Mab Llc | Postopki spreminjanja rasti kosti z dajanjem antagonista ali agonista SOST ali WISE |
| JP5385257B2 (ja) | 2007-03-26 | 2014-01-08 | バクスター・インターナショナル・インコーポレイテッド | 軟部組織増強のための注入可能な空隙の充填剤 |
| CA2686820C (en) * | 2007-04-23 | 2016-06-28 | Baxter International Inc. | Fibrin compositions containing strontium compounds |
| CA2685407A1 (en) * | 2007-04-27 | 2008-11-06 | Yale University | Methods and compositions for fostering and preserving bone growth |
| WO2008157608A1 (en) * | 2007-06-18 | 2008-12-24 | Cartlix, Inc. | Composite scaffolds for tissue regeneration |
| CA2702190A1 (en) * | 2007-10-12 | 2009-04-16 | Kuros Biosurgery Ag | Injectable radio-opaque compositions for tissue augmentation |
| EP2227263A2 (en) * | 2007-12-28 | 2010-09-15 | Kuros Biosurgery AG | Pdgf fusion proteins incorporated into fibrin foams |
| EP2279021B1 (en) | 2008-04-18 | 2013-02-13 | Kuros Biosurgery AG | Dispensing device, kit containing the device, and method of operating the device |
| WO2011031476A2 (en) * | 2009-08-25 | 2011-03-17 | Emory University | Compositions and methods for treatment or prevention of post-operative organ or tissue inflammation |
| KR101114773B1 (ko) * | 2009-10-23 | 2012-03-05 | 세원셀론텍(주) | 연골조직 수복용 조성물의 제조방법 |
| ES2882852T3 (es) | 2011-03-16 | 2021-12-02 | Kuros Biosurgery Ag | Formulación farmacéutica para la utilización en la fusión espinal |
| US8404256B2 (en) * | 2011-05-06 | 2013-03-26 | The University Of Memphis Research Foundation | Biomaterial composite composition and method of use |
| RU2563992C2 (ru) * | 2013-08-12 | 2015-09-27 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) | Композитные матриксы на основе фиброина шелка, желатина и гидроксиапатита для регенерации костной ткани |
| EP3536353A1 (en) * | 2018-03-09 | 2019-09-11 | Kuros Biosurgery AG | Method and kits for producing a fibrin matrix |
| RU2702520C1 (ru) * | 2019-04-17 | 2019-10-08 | Анна Владимировна Алабут | Способ эндопротезирования коленного сустава у пациентов с остеопорозом |
| RU2764373C1 (ru) * | 2021-03-29 | 2022-01-17 | Федеральное государственное бюджетное военное образовательное учреждение высшего образования "Военно-медицинская академия имени С.М. Кирова" Министерства обороны Российской Федерации (ВМедА) | Способ применения ген-активированного материала при несращениях длинных костей |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4086196A (en) | 1975-03-28 | 1978-04-25 | Armour Pharmaceutical Company | Parathyroid hormone |
| SE8200751L (sv) * | 1982-02-09 | 1983-08-10 | Olle Larm | Forfarande for kovalent koppling for framstellning av konjugat och hervid erhallna produkter |
| IL74617A (en) * | 1985-03-15 | 1988-11-15 | Yeda Res & Dev | Compositions comprising a vitamin d derivative and method for the local treatment of bone fractures in animals |
| US5504001A (en) * | 1987-11-25 | 1996-04-02 | Zymogenetics, Inc. | Hybrid plasminogen activator |
| US5582862A (en) * | 1988-04-04 | 1996-12-10 | General Hospital Corporation | Antibodies that bind to α2-antiplasmin crosslinked to fibrin which do not inhibit plasma α2-antiplasmin |
| US5100668A (en) * | 1988-06-14 | 1992-03-31 | Massachusetts Institute Of Technology | Controlled release systems containing heparin and growth factors |
| US5137819A (en) * | 1988-07-08 | 1992-08-11 | University Of British Columbia | Cellulose binding fusion proteins for immobilization and purification of polypeptides |
| US5171670A (en) * | 1989-05-12 | 1992-12-15 | The General Hospital Corporation | Recombinant dna method for production of parathyroid hormone |
| US6054122A (en) * | 1990-11-27 | 2000-04-25 | The American National Red Cross | Supplemented and unsupplemented tissue sealants, methods of their production and use |
| US6117425A (en) * | 1990-11-27 | 2000-09-12 | The American National Red Cross | Supplemented and unsupplemented tissue sealants, method of their production and use |
| US6197325B1 (en) * | 1990-11-27 | 2001-03-06 | The American National Red Cross | Supplemented and unsupplemented tissue sealants, methods of their production and use |
| US6559119B1 (en) * | 1990-11-27 | 2003-05-06 | Loyola University Of Chicago | Method of preparing a tissue sealant-treated biomedical material |
| SE470006B (sv) * | 1991-09-26 | 1993-10-25 | Corline Systems Ab | Nytt konjugat, dess framställning och användning samt substrat preparerat med konjugatet |
| US5641670A (en) * | 1991-11-05 | 1997-06-24 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
| US5814603A (en) * | 1992-06-12 | 1998-09-29 | Affymax Technologies N.V. | Compounds with PTH activity |
| US5589452A (en) * | 1992-07-14 | 1996-12-31 | Syntex (U.S.A.) Inc. | Analogs of parathyroid hormone and parathyroid hormone related peptide: synthesis and use for the treatment of osteoporosis |
| US5428014A (en) * | 1993-08-13 | 1995-06-27 | Zymogenetics, Inc. | Transglutaminase cross-linkable polypeptides and methods relating thereto |
| US5773577A (en) * | 1994-03-03 | 1998-06-30 | Protein Polymer Technologies | Products comprising substrates capable of enzymatic cross-linking |
| US5747456A (en) * | 1994-12-19 | 1998-05-05 | Beth Israel Deaconess Medical Center | Continuous low-dose administration of parathyroid hormone or its agonist |
| US5693341A (en) * | 1995-03-16 | 1997-12-02 | Collagen Corporation | Affinity bound collagen matrices for the delivery of biologically active agents |
| US5561983A (en) * | 1995-07-10 | 1996-10-08 | Caire, Inc. | Cryogenic liquid delivery system |
| JP2000500019A (ja) * | 1995-11-16 | 2000-01-11 | ロシュ ダイアグノスティクス ゲゼルシャフト ミット ベシュレンクテル ハフツング | ストレプトアビジン融合タンパク質経由でのペプチドの生産方法 |
| ES2420106T3 (es) * | 1995-12-18 | 2013-08-22 | Angiodevice International Gmbh | Composiciones de polímeros reticulados y métodos para su uso |
| US5874308A (en) * | 1996-01-16 | 1999-02-23 | University Of British Columbia | Compositions and methods for modulating cell proliferation using growth factor-polysaccharide binding fusion proteins |
| US6221854B1 (en) * | 1996-03-05 | 2001-04-24 | Orquest, Inc. | Method of promoting bone growth with hyaluronic acid and growth factors |
| US5877153A (en) * | 1996-06-11 | 1999-03-02 | Commonwealth Biotechnologies Inc. | Heparin-binding peptides |
| GB2348426B (en) | 1997-04-03 | 2001-06-27 | California Inst Of Techn | Enzyme-mediated modification of fibrin for tissue engineering |
| US20020168718A1 (en) * | 1997-04-03 | 2002-11-14 | California Institute Of Technology | Enzyme-mediated modification of fibrin for tissue engineering |
| US5958874A (en) * | 1998-02-18 | 1999-09-28 | The Research Foundation Of State University Of New York | Recombinant fibronectin-based extracellular matrix for wound healing |
| DE19816858A1 (de) * | 1998-04-16 | 1999-10-21 | Merck Patent Gmbh | Tricalciumphosphathaltige Biozementpasten mit Kohäsionspromotoren |
| US7241730B2 (en) * | 1998-08-27 | 2007-07-10 | Universitat Zurich | Enzyme-mediated modification of fibrin for tissue engineering: fibrin formulations with peptides |
| US7601685B2 (en) * | 1998-08-27 | 2009-10-13 | Eidgenossische Technische Hochschule Zurich | Growth factor modified protein matrices for tissue engineering |
| US6894022B1 (en) * | 1998-08-27 | 2005-05-17 | Eidgenossische Technische Hochschule Zurich | Growth factor modified protein matrices for tissue engineering |
| US6663870B2 (en) * | 1998-12-07 | 2003-12-16 | Zymogenetics, Inc. | Methods for promoting growth of bone using zvegf3 |
| US6468543B1 (en) * | 1999-05-03 | 2002-10-22 | Zymogenetics, Inc. | Methods for promoting growth of bone using ZVEGF4 |
| US6303138B1 (en) * | 1999-09-17 | 2001-10-16 | Depuy Orthopaedics | Endothelin-based compositions for enhancing connective tissue repair |
| US7052856B2 (en) * | 1999-10-05 | 2006-05-30 | The Regents Of The University Of California | NELL-1 enhanced bone mineralization |
| US6608293B2 (en) * | 1999-12-17 | 2003-08-19 | Agilent Technologies Inc. | Method of and apparatus for testing a photosensor |
| US6811776B2 (en) * | 2000-12-27 | 2004-11-02 | The Regents Of The University Of Michigan | Process for ex vivo formation of mammalian bone and uses thereof |
| US6949251B2 (en) * | 2001-03-02 | 2005-09-27 | Stryker Corporation | Porous β-tricalcium phosphate granules for regeneration of bone tissue |
| CA2367636C (en) * | 2001-04-12 | 2010-05-04 | Lisa Mckerracher | Fusion proteins |
| EP1406678B1 (en) * | 2001-04-25 | 2009-01-14 | Eidgenössische Technische Hochschule Zürich | Drug delivery matrices to enhance wound healing |
| US20070264227A1 (en) * | 2001-11-07 | 2007-11-15 | Eidgenossische Technische Hochschule Zurich | Synthetic Matrix for Controlled Cell Ingrowth and Tissue Regeneration |
| BR0213937A (pt) * | 2001-11-07 | 2004-10-26 | Univ Zuerich | Matriz sintética para encravamento celular controlado e regeneração de tecido |
| US7247609B2 (en) * | 2001-12-18 | 2007-07-24 | Universitat Zurich | Growth factor modified protein matrices for tissue engineering |
| MXPA04006021A (es) * | 2001-12-18 | 2005-08-19 | Eth Zuerich | Matrices de proteina modificada con factor de crecimiento para ingenieria de tejidos. |
| WO2003055418A1 (en) * | 2001-12-21 | 2003-07-10 | Lagow Richard J | Calcium phosphate bone replacement materials and methods of use thereof |
| CA2483778A1 (en) * | 2002-04-29 | 2003-11-13 | Gel-Del Technologies, Inc. | Biomatrix structural containment and fixation systems and methods of use thereof |
| US20050010297A1 (en) * | 2003-05-08 | 2005-01-13 | Kuros Biosurgery Ag | Balloon technologies for tissue repair |
| DE10355992A1 (de) * | 2003-11-27 | 2005-06-30 | Curasan Ag | Bioresorbierbares Kompositmaterial |
| JP2008529972A (ja) * | 2004-12-22 | 2008-08-07 | クロス・バイオサージェリー・アクチェンゲゼルシャフト | 酵素的に分解可能な連結を通じて生物活性因子が組み入れられている合成バイオマテリアル |
| WO2006073711A2 (en) * | 2005-01-06 | 2006-07-13 | Kuros Biosurgery Ag | Use of a matrix comprising a contrast agent in soft tissues |
| US20060168718A1 (en) * | 2005-02-01 | 2006-08-03 | Frederick Watson | Urinal enclosure |
-
2006
- 2006-01-06 KR KR1020077018079A patent/KR20070108170A/ko not_active Application Discontinuation
- 2006-01-06 EP EP16175576.4A patent/EP3111966B1/en active Active
- 2006-01-06 ES ES16175576T patent/ES2902872T3/es active Active
- 2006-01-06 RU RU2007129844/15A patent/RU2422172C2/ru not_active IP Right Cessation
- 2006-01-06 ES ES06707674.5T patent/ES2593051T3/es active Active
- 2006-01-06 EP EP06707674.5A patent/EP1833522B1/en active Active
- 2006-01-06 JP JP2007549892A patent/JP5328153B2/ja not_active Expired - Fee Related
- 2006-01-06 SG SG201002289-5A patent/SG161218A1/en unknown
- 2006-01-06 AU AU2006204461A patent/AU2006204461C1/en not_active Ceased
- 2006-01-06 MX MX2007008319A patent/MX2007008319A/es active IP Right Grant
- 2006-01-06 EP EP10181752.6A patent/EP2316497A3/en not_active Withdrawn
- 2006-01-06 BR BRPI0606409-4A patent/BRPI0606409A2/pt active Search and Examination
- 2006-01-06 CA CA002592973A patent/CA2592973A1/en not_active Abandoned
- 2006-01-06 WO PCT/EP2006/050069 patent/WO2006072622A2/en active Application Filing
- 2006-01-06 US US11/327,214 patent/US20060148704A1/en not_active Abandoned
-
2013
- 2013-04-22 JP JP2013089407A patent/JP2013173770A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| EP1833522B1 (en) | 2016-06-22 |
| BRPI0606409A2 (pt) | 2009-06-23 |
| RU2422172C2 (ru) | 2011-06-27 |
| EP2316497A3 (en) | 2014-05-07 |
| WO2006072622A3 (en) | 2006-11-23 |
| EP3111966A1 (en) | 2017-01-04 |
| EP2316497A2 (en) | 2011-05-04 |
| EP3111966B1 (en) | 2021-10-13 |
| JP2013173770A (ja) | 2013-09-05 |
| WO2006072622A2 (en) | 2006-07-13 |
| AU2006204461B2 (en) | 2011-07-07 |
| AU2006204461A1 (en) | 2006-07-13 |
| JP2008526810A (ja) | 2008-07-24 |
| EP1833522A2 (en) | 2007-09-19 |
| AU2006204461C1 (en) | 2012-01-12 |
| ES2902872T3 (es) | 2022-03-30 |
| MX2007008319A (es) | 2007-10-04 |
| ES2593051T3 (es) | 2016-12-05 |
| US20060148704A1 (en) | 2006-07-06 |
| KR20070108170A (ko) | 2007-11-08 |
| JP5328153B2 (ja) | 2013-10-30 |
| SG161218A1 (en) | 2010-05-27 |
| CA2592973A1 (en) | 2006-07-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2007129844A (ru) | Дополненные матриксы для лечения переломов костей | |
| Zalavras et al. | Management of open fractures and subsequent complications | |
| ES2183606T3 (es) | Granulado de adhesivo de fibrina y procedimiento para su preparacion. | |
| HUP0401357A2 (hu) | Kalcium-foszfát hordozóanyagok csontképződést serkentő fehérjék bejuttatásához | |
| BR0317896A (pt) | Complexos de cristais de proteìna e polìmeros iÈnicos | |
| BR0110659A (pt) | Composição farmacêutica, kit, uso de um fator viia em combinação com um fator, xiii, e, métodos para intensificação da formação de coágulo de fibrina em um indivìduo e para tratar de episódios de hemorragia em um indivìduo | |
| MX2009001323A (es) | Aposito solido para tratar tejido herido. | |
| MXPA03006771A (es) | Anticuerpos modificados y metodos de uso. | |
| ATE447895T1 (de) | Knochenfraktur-fixationssystem mit subchondraler und artikulärer oberflächenunterstützung | |
| NO2014010I1 (no) | Radium 223 salt slik som Radium 223 diklorid | |
| EA200801073A1 (ru) | Фармацевтическая композиция, содержащая лактат, и ее применение | |
| WO2008082563A3 (en) | Sustained-release formulations comprising crystals, macromolecular gels, and particulate suspensions of biologic agents | |
| CY1113286T1 (el) | Συνθεση με στροντιο και βιταμινη d για την προφυλαξη ή/καιθεραπευτικη αντιμετωπιση των παθησεων των χονδρων ή/και των οστων | |
| DE60313597D1 (de) | Topische pharmazeutische zusammensetzungen mit proanthocyanidinen, glycyrrhetinic säure und telmesteine zur behandlung von dermatitis | |
| BR0106649A (pt) | Composição fertilizante contendo enxofre e processo para preparação da mesma | |
| CA2454584A1 (en) | Pharmaceutical composition for treatment of diseases associated with decrease in bone mass comprising ep4 agonist as active ingredient | |
| TW200501947A (en) | Stabilized pharmaceutical composition comprising an amorphous active substance | |
| Ueng et al. | Management of large infected tibial defects with radical debridement and staged double-rib composite free transfer | |
| EE200200155A (et) | Antibiootilise kompositsiooni valmistamismeetod, selle meetodi abil saadud kompositsioon ja selle kasutamine | |
| BR0200876A (pt) | Preparação de antibiótico/antibióticos com liberação retardada de substância ativa | |
| Zalavras et al. | Reconstruction of large skeletal defects due to osteomyelitis with the vascularized fibular graft in children | |
| BR9915018A (pt) | Modificação de cristal da torasemida | |
| WO2001097871A3 (en) | Collagen hemostatic pellets | |
| ATE446763T1 (de) | Pharmazeutische formulierung zur behandlung von osteoarthritis mit clodronsäure und hyaluronsäure | |
| Ren et al. | A neglected problem in the utilization of free anterolateral thigh flap toward reconstructing complicated wounds of extremities: the obliteration of deep dead space |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20160107 |